Handa Pharmaceuticals (6620) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 漢達

Handa Pharmaceuticals (6620) reported revenue of NT$65.9 million for Oct 2026, -24.8% year on year and -6.5% from the previous month. Revenue for Jan–Oct 2026 was NT$696.3 million (-54.1% year on year).

In Oct 2026, it ranked No. 92 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$65.1 million24/10Nov 2024 NT$55.9 millionDec 2024 NT$66.3 millionJan 2025 NT$57.3 millionFeb 2025 NT$52.7 million25/02Mar 2025 NT$70.9 millionApr 2025 NT$561.2 millionMay 2025 NT$94.2 millionJun 2025 NT$103.4 million25/06Jul 2025 NT$69.3 millionAug 2025 NT$332.1 millionSep 2025 NT$88.1 millionOct 2025 NT$87.6 million25/10Nov 2025 NT$75.8 millionDec 2025 NT$136.8 millionJan 2026 NT$75.7 millionFeb 2026 NT$55 million26/02Mar 2026 NT$78.7 millionApr 2026 NT$62.1 millionMay 2026 NT$71.3 millionJun 2026 NT$80.9 million26/06Jul 2026 NT$69.7 millionAug 2026 NT$66.7 millionSep 2026 NT$70.4 millionOct 2026 NT$65.9 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$65.9 million-24.8%-6.5%
Sep 2026NT$70.4 million-20.1%+5.6%
Aug 2026NT$66.7 million-79.9%-4.3%
Jul 2026NT$69.7 million+0.6%-13.9%
Jun 2026NT$80.9 million-21.8%+13.5%
May 2026NT$71.3 million-24.4%+14.8%
Apr 2026NT$62.1 million-88.9%-21.1%
Mar 2026NT$78.7 million+11.0%+43.2%
Feb 2026NT$55 million+4.2%-27.4%
Jan 2026NT$75.7 million+32.2%-44.7%
Dec 2025NT$136.8 million+106.5%+80.5%
Nov 2025NT$75.8 million+35.6%-13.4%
Oct 2025NT$87.6 million+34.4%-0.6%
Sep 2025NT$88.1 million+37.7%-73.5%
Aug 2025NT$332.1 million+410.9%+379.6%
Jul 2025NT$69.3 million-14.2%-33.0%
Jun 2025NT$103.4 million+23.0%+9.8%
May 2025NT$94.2 million+28.0%-83.2%
Apr 2025NT$561.2 million+870.8%+691.4%
Mar 2025NT$70.9 million+19.9%+34.5%
Feb 2025NT$52.7 million-25.3%-7.9%
Jan 2025NT$57.3 million-34.7%-13.6%
Dec 2024NT$66.3 million-41.8%+18.5%
Nov 2024NT$55.9 million-39.4%-14.2%
Oct 2024NT$65.1 million-21.6%+1.8%

Jan–Oct 2026 cumulative: NT$696.3 million (-54.1% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Handa Pharmaceuticals vs PEC / Handa Pharmaceuticals vs Lotus Pharm / Handa Pharmaceuticals vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

Company remark (original Chinese)

營收差異主要係114年4月及8月認列Phyrago授權相關收入所致

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16